US Peptide Science Research Team
September 8, 2026
Peptides are short chains of amino acids that mediate neurotransmission, neuromodulation, and cellular signaling in the central nervous system. Selank (also designated TP-7, Selanc, or threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline) is a synthetic heptapeptide originally developed in Russia that has emerged as a research compound of significant interest for its anxiolytic and cognitive-enhancing properties in preclinical and clinical models. Unlike traditional peptide structure inquiries, Selank represents a distinct class of neuropeptide pharmacology with research applications in anxiety and stress-related disorders.
Clinical research has established that Selank produces anxiolytic effects comparable to classical benzodiazepines such as medazepam in controlled trials, yet without the characteristic side effects associated with GABAergic receptor agonism. A clinical trial comparing Selank (30 patients) to medazepam (32 patients) in patients with generalized anxiety disorder (GAD) and neurasthenia found equivalent anxiolytic efficacy on standardized rating scales; however, Selank demonstrated additional antiasthenic and psychostimulant effects absent in the traditional benzodiazepine comparator klarovel.com.
Critically, Selank research has not documented the unwanted sequelae characteristic of benzodiazepine use: amnesia, cognitive impairment, withdrawal syndrome, or dependence liability in available studies. This pharmacological profile distinguishes Selank within the anxiolytic research class and has motivated investigation into its underlying molecular mechanisms.
Benzodiazepines function as allosteric modulators of GABAA receptors, enhancing the inhibitory action of γ-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system. The similarity between Selank's clinical effects and those of benzodiazepines suggests comparable allosteric modulation of GABAergic signaling, yet the mechanistic basis remains incompletely characterized.
To elucidate Selank's molecular mechanism, researchers administered Selank or GABA to male Wistar rats and analyzed expression of 84 genes involved in neurotransmission using quantitative real-time PCR in frontal cortex tissue . Key findings included:
These findings indicate that Selank produces complex, time-dependent alterations in neurotransmission-related gene expression that partially overlap with but are not identical to GABA-induced changes. The positive correlation at early timepoints supports the hypothesis of GABAergic system modulation; however, the divergence at later timepoints suggests engagement of alternative signaling pathways.
Cell culture studies using IMR-32 neuroblastoma cells revealed a more nuanced mechanistic picture. When Selank was applied alone, no significant changes in mRNA levels of GABAergic system genes were observed peptidedosages.com. However, when Selank was combined with GABA, the peptide modulated the gene expression changes induced by GABA alone—a finding suggesting Selank may modulate GABA's interaction with GABAA receptors rather than directly affecting GABAergic gene transcription.
Research indicates that Selank may function as a positive allosteric modulator of GABAA receptors with subtype selectivity, distinct from the benzodiazepine binding site klarovel.com. This allosteric modulation hypothesis remains mechanistically plausible but requires further structural and binding studies for confirmation.
Beyond GABAergic mechanisms, research suggests Selank may modulate endogenous opioid neuropeptide systems. Clinical studies measuring enkephalin activity in blood serum of GAD and neurasthenia patients demonstrated that these populations exhibit decreased leu-enkephalin levels, a marker inversely correlated with disease severity. During Selank treatment in research settings, leu-enkephalin levels increased, with positive correlations observed between enkephalin elevation and anxiety symptom reduction in GAD patients klarovel.com.
This biomarker-level evidence suggests that Selank's anxiolytic mechanism may involve activation or upregulation of endogenous enkephalin signaling, a distinct pathway from direct GABAergic agonism. Enkephalins function as endogenous ligands at opioid receptors and modulate stress responses and emotional processing—mechanisms potentially contributing to Selank's anxiolytic properties in research models.
Beyond anxiolysis, research indicates Selank exhibits nootropic activity in preclinical models. Animal studies demonstrate Selank positively influences memory formation and learning processes, effects distinct from the cognitive impairment associated with benzodiazepine use. Biomarker studies have documented measurable increases in serum brain-derived neurotrophic factor (BDNF) following Selank administration in research settings, suggesting engagement of neuroplasticity mechanisms relevant to cognitive function and neuroprotection empiremedicaltraining.com.
These findings position Selank within a distinct pharmacological category in research contexts: an anxiolytic agent with concurrent nootropic and potentially neuroprotective properties—a profile uncommon among classical anxiolytics.
Preclinical research has identified immunomodulatory activity associated with Selank administration in animal models. Studies document alterations in immune cell populations and inflammatory biomarkers, suggesting the peptide may exert broader systemic effects beyond central nervous system-restricted anxiolysis. The mechanisms underlying immunomodulation remain incompletely characterized but may involve neuropeptide-immune system cross-talk or direct effects on immune cell receptors.
The temporal profile of Selank's molecular effects warrants emphasis. Gene expression changes peak at 1 hour post-administration and partially normalize by 3 hours in animal models, suggesting a relatively acute pharmacodynamic window. This temporal pattern differs from classical benzodiazepines, which typically exhibit longer pharmacological half-lives and sustained receptor occupancy. Research has identified specific doses in animal models as producing measurable molecular effects, though human equivalent dosing and dose-response relationships in clinical populations remain incompletely defined.
While available evidence supports Selank's anxiolytic efficacy in research models and identifies plausible molecular mechanisms involving GABAergic allosteric modulation, enkephalin system activation, and complex neurotransmission-related gene expression changes, substantial gaps remain:
Selank represents a novel peptide anxiolytic in research contexts with a distinct pharmacological profile: anxiolytic efficacy comparable to benzodiazepines in controlled trials without documented sedation, dependence, or cognitive impairment in available studies. Emerging mechanistic research identifies complex interactions with GABAergic signaling, endogenous enkephalin systems, and broader neurotransmission-related gene expression. The peptide's concurrent nootropic and immunomodulatory effects in preclinical models distinguish it from classical anxiolytics and warrant further investigation into potential research applications in anxiety disorders, stress-related conditions, and possibly cognitive decline. Future research employing advanced neuroimaging, receptor binding studies, and Western clinical validation will be essential to fully characterize Selank's mechanisms and optimize its research potential.
Key takeaways: